Join to View Full Profile
213 Quarry RdPalo Alto, CA 94304
Dr. Omuro is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Universidade de Sao Paulo Faculty of MedicineClass of 1994
Certifications & Licensure
NY State Medical License 2008 - 2027
CT State Medical License Active through 2026
FL State Medical License 2017 - 2019
Clinical Trials
- Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Start of enrollment: 2007 Jun 01
- Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine Start of enrollment: 2007 Jul 01
- Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Start of enrollment: 2002 Sep 01
Publications & Presentations
PubMed
- Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma.Antonio Omuro, Lisa M DeAngelis, Mei-Yin C Polley, Denise Correa, Jeffrey S Wefel
Neuro-Oncology. 2025-11-04 - Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas.David Schiff, Xiaobu Ye, Jing Li, Benjamin M Ellingson, Patrick Y Wen
Neuro-Oncology. 2025-10-16 - 7 citationsAdvances in Primary Central Nervous System Lymphoma.Kate E Therkelsen, Antonio Omuro
Current Neurology and Neuroscience Reports. 2024-11-25
Journal Articles
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaDavid A Reardon, Antonio Omuro, Joachim Baehring, Surasak Phuphanich, Solmaz Sahebjam, JAMA Oncology
Authored Content
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
- Effect of Nivolumab vs Bevacizumab in Patients with Recurrent GlioblastomaMay 2020
Press Mentions
Tactical Therapeutics New Drug Carboxyamidotriazole Orotate (CTO) Is Getting Notoriety for Its Success in Treating Brain Cancer Patients Who Went Through a Phase 1 Trial at the Memorial Sloan Kettering Cancer Center in New York, NYDecember 6th, 2022- While Doctors Cut Out His Brain Tumor, He Sang ’80s SongsNovember 16th, 2019
Grant Support
- Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122YALE UNIVERSITY2022–2026
- Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122YALE UNIVERSITY2022–2026
Professional Memberships
- Member
Other Languages
- Portuguese, French, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
